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vertebral, hip and wrist fracture or death (either natural or excess mortality due to 
fracture). Swedish data on fracture costs, utility reductions after fracture, fracture risks 
and mortality rates were used. Uncertainty was investigated using one-way and proba-
bilistic sensitivity analyses. Costs and utilities were discounted at annual discount rates 
of 3%. RESULTS: The analyzed cohort comprised patients aged 69 years (80% 
female) with a BMD T-Score of −2.5 SD and an historical vertebral fracture (5 years 
previous) and an incident vertebral fracture. In the base-case analysis of this cohort 
the costs in the teriparatide treatment group were 558,918 SEK per patient compared 
to 552,026 SEK in the no teriparatide group. The cost per QALY gained of teriparatide 
compared to no teriparatide was estimated to be SEK 25,000. The results were robust 
under a wide range of assumptions. CONCLUSIONS: For the analyzed cohorts, the 
base-case and one-way sensitivity analyses performed indicate that an 18-month 
teriparatide regimen versus no treatment in patients with glucocorticoid induced 
osteoporosis is cost-effective from the perspective of the Swedish payer.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic, progressive, inﬂ ammatory 
disease that affects physical functioning and quality-of-life and is associated with 
premature mortality and substantial economic burden. We aimed to assess the cost-
effectiveness of tocilizumab added to disease-modifying antirheumatic drugs 
(DMARD) in patients with active RA despite DMARD therapy from the perspective 
of public health care system in Costa Rica. METHODS: A decision analysis was 
carried out to compare tocilizumab 8 mg/kg given every 4 weeks; inﬂ iximab 3 mg/kg 
(weeks 0, 2, 6, 14) and 5 mg/kg (every 8 weeks from week 22); etanercept 25 mg 
given twice a week and adalimumab 40 mg given every other week. The model 
included acquisition costs of biological agents during ﬁ rst year of treatment besides 
infusion-related costs for inﬂ iximab and tocilizumab. Indirect comparison techniques 
were needed to adjust American College of Rheumatology (ACR) responses rates 
found in 10 placebo-controlled clinical trials with biological agents used as add-on 
therapy to DMARD. ACR70 response rate, which can be regarded as a close measure 
of remission, was selected as primary efﬁ cacy outcome. Unitary costs were gathered 
from the 2010 Ofﬁ cial Price List of the Public Health Care System in Costa Rica. All 
costs are expressed in 2010 US dollars. RESULTS: First-year costs for an average 
70 kg weight patient were lower with tocilizumab (US$12,272) than with etanercept 
(US$13,000), adalimumab (US$13,650) and inﬂ iximab (US$14,340). Adjusted 
ACR70 response rate was higher for tocilizumab (26%) than for adalimumab (19%), 
etanercept (18%) and inﬂ iximab (12%). Incremental cost per patient achieving an 
ACR70 response with tocilizumab instead of anti-tumor necrosis factor (TNF) agents 
were estimated at −US$9,100, −US$14,771 and −US$19,686 for etanercept, adalim-
umab and inﬂ iximab, respectively. CONCLUSIONS: When used instead of anti-TNF 
agents, add-on treatment with tocilizumab brings both health beneﬁ ts and cost-savings 
for RA patients with inadequate response to previous DMARD therapy.
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OBJECTIVES: Abatacept in combination with MTX has recently been granted a 
positive opinion from the European Medicines Agency for use for the treatment of 
moderate to severe active rheumatoid arthritis in adult patients who responded inad-
equately to previous therapy with one or more conventional disease-modifying anti-
rheumatic drugs (cDMARDs) including methotrexate (MTX). This analysis explores 
the cost-effectiveness of abatacept in this new indication. METHODS: A patient-
simulation treatment-sequence economic model was constructed to estimate the incre-
mental cost per quality adjusted life-year (QALY) for patients with RA in the United 
Kingdom. Abatacept with MTX , followed by a sequence of DMARDs was compared 
against a sequence of cDMARDs. Treatment-speciﬁ c efﬁ cacy in terms of Health 
Assessment Questionnaire (HAQ) was used to calculate the patient’s utility medical 
resource use and cost over a lifetime. Mortality was HAQ dependent. The analysis is 
performed from a National Health Service. Costs and outcomes were discounted at 
3.5% each. RESULTS: Abatacept with MTX was estimated to yield 1.09 QALYs per 
patient (6.42 vs. 5.33) over lifetime, compared to DMARDs. The total lifetime costs 
associated with abatacept with MTX were £110,094 and total costs for cDMARDs 
were £79,933 resulting in an incremental cost-effectiveness ratio (ICER) of £27,657 
per QALY gained. Sensitivity analysis conﬁ rmed the robustness of the model ﬁ ndings. 
CONCLUSIONS: This study has demonstrated that abatacept with MTX is a cost-
effective treatment option compared to cDMARDs for patients with rheumatoid 
arthritis after an inadequate response to MTX.
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OBJECTIVES: About 30% of patients treated with an anti-TNF agent failed to 
achieve an improvement of 20% in American College of Rheumatology (ACR) 
response. Recent clinical practice guidelines recommend the use of rituximab after 
previous failure of one anti-TNF. This study aims to assess the cost-effectiveness of 
rituximab compared to cycling between anti-TNF agents in this population from the 
perspective of the public health care system in Mexico. METHODS: A decision analy-
sis was carried out to compare 2 rituximab courses (1 course, consisting of 2 infusions 
of 1 g each) given 6 months apart; inﬂ iximab 3 mg/kg (weeks 0, 2, 6, 14) and 5 mg/
kg (weeks 22, 30, 38 and 46); etanercept 25 mg twice a week and adalimumab 40 mg 
every other week. Only direct medical costs cumulated during a one-year timeframe 
were accounted for and these included acquisition cost of biologic drugs besides infu-
sion costs for rituximab and inﬂ iximab. Primary efﬁ cacy outcome was deﬁ ned as an 
improvement of 70% in ACR response (ACR70), which is a close measure of remis-
sion. Indirect comparison techniques were used to adjust ACR responses rates found 
in 9 clinical trials. Number needed to treat (NNT) to obtain an ACR70 was then 
calculated. All costs are reported in 2009 US dollars (USD). RESULTS: For a 70 Kg 
patient, annual mean costs were estimated at USD$13,025 for rituximab, USD$12,938 
for inﬂ iximab, USD$12,226 for adalimumab and USD$10,850 for etanercept. 
Adjusted ACR70 rates were higher in rituximab (12.4%) than in adalimumab (9.0%), 
etanercept (8.2%) and inﬂ iximab (5.4%). Average cost to achieve an ACR70 was 
lower with rituximab (USD$105,047) than with anti-TNF therapies, leading to savings 
of USD$27,270; USD$30,797 and USD$134,543 compared to etanercept, adalim-
umab and inﬂ iximab, respectively. CONCLUSIONS: This study suggests that ritux-
imab treatment after previous failure of one anti-TNF agent is a cost-effective strategy 
compared to cycling between anti-TNF agents.
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OBJECTIVES: About 30% of patients treated with an anti-TNF agent failed to 
achieve an improvement of 20% in American College of Rheumatology (ACR) 
response. Recent clinical practice guidelines recommend the use of rituximab after 
previous failure of one anti-TNF. This study aims to assess the cost-effectiveness of 
rituximab compared to cycling between anti-TNF agents in this population from the 
perspective of public health care system in Costa Rica. METHODS: A decision analy-
sis was carried out to compare 2 rituximab courses (1 course, consisting of 2 infusions 
of 1 g each) given 6 months apart; inﬂ iximab 3 mg/kg (weeks 0, 2, 6, 14) and 5 mg/
kg (weeks 22, 30, 38 and 46); etanercept 25 mg twice a week and adalimumab 40 mg 
every other week. Only direct medical costs cumulated during a one-year timeframe 
were accounted for and these included acquisition cost of biologic drugs besides infu-
sion costs for rituximab and inﬂ iximab. Primary efﬁ cacy outcome was deﬁ ned as an 
improvement of 70% in ACR response (ACR70), which is a close measure of remis-
sion. Indirect comparison techniques were used to adjust ACR responses rates found 
in 9 clinical trials. Number needed to treat (NNT) to obtain an ACR70 was then 
calculated. All costs are reported in 2009 US dollars (USD). RESULTS: For a 70 Kg 
patient, annual mean costs were estimated at US$15,040 for rituximab, US$14,340 
for inﬂ iximab, US$13,650 for adalimumab, and US$13,000 for etanercept. Adjusted 
ACR70 rates were higher in rituximab (12.4%) than in adalimumab (9.0%), etaner-
cept (8.2%) and inﬂ iximab (5.4%). Average cost to achieve an ACR70 was lower 
with rituximab (US$121,290) than with anti-TNF therapies, leading to savings of 
US$30,377; US$37,247; and US$144,266 compared to etanercept, adalimumab and 
inﬂ iximab, respectively. CONCLUSIONS: This study suggests that rituximab treat-
ment after previous failure of one anti-TNF agent is a cost-effective strategy compared 
to cycling between anti-TNF agents.
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OBJECTIVES: Denosumab represents a new therapeutic opportunity for the treatment 
of osteoporosis, that received a positive opinion from the European Committee for 
Medical Products for Human Use in December 2009. This study aims to evaluate the 
cost-effectiveness of denosumab compared with the most relevant alternative (i.e. 
generic alendronate) in the treatment of postmenopausal osteoporotic women. 
METHODS: The cost-effectiveness of treatment for 3-years with denosumab was 
compared with generic alendronate using an updated version of a previously validated 
Markov microsimulation model (Value Health 2009:12:687–96). The model was 
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populated with relevant cost, adherence and epidemiological data for Belgium from a 
health care perspective and the results were presented in cost (c2009) per quality-
adjusted life-year (QALY) gained. Analyses were performed in populations (over 60 
years) where osteoporosis medications are currently reimbursed in many European 
countries, i.e. bone mineral density T-score is below or equal to −2.5 or presence of 
prevalent vertebral fracture. Univariate and probabilistic sensitivity analyses were 
conducted to assess the robustness of the results. RESULTS: The cost-effectiveness of 
denosumab compared with generic alendronate was estimated at c38,875, c20,690 
and c26,153 per QALY for women with T-score ≤−2.5 aged 60, 70 and 80 years, 
respectively. The equivalent values were c37,856, c18,764 and c17,309 per QALY 
for women with prevalent vertebral fractures. Discount rates, fracture risk and 
patient’s adherence to generic alendronate were found to be particularly sensitive when 
varied within the model. At 70 years of age, probabilistic sensitivity analyses showed 
that the probability of the ICERs remaining below c40,000 is 84% in women with 
prevalent vertebral fracture and 74% in those with T-score ≤−2.5, conﬁ rming the 
cost-effectiveness of denosumab. CONCLUSIONS: This study suggests that deno-
sumab is a cost-effective strategy (cost per QALY gained ≤c40,000) compared with 
generic alendronate for the treatment of postmenopausal Belgian osteoporotic women, 
aged 60 years and above.
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OBJECTIVES: Current osteoporosis therapies can reduce the risk of fractures and 
thus costs, but adherence to these medications is often poor. We estimated yearly 
potential savings in fracture-related costs from improved adherence to osteoporosis 
therapies in Germany from a societal perspective. METHODS: The model was a 
deterministic cohort model estimating annual treatments and outcomes for German 
women aged ≥50 years old in 2010 (n = 17,689,849), by f5 year cohorts. Demographic 
parameters were drawn from government databases, medication prescription share 
from industry databases, fracture incidence (hip, clinical vertebral, and non-hip, non 
vertebral (NHNV)), medication adherence (medication possession ratio MPR, one 
year intervals) and efﬁ cacy from published literature. As a base case we estimated 
4.2% treated (n = 745,313) with oral bisphosphonates (94.6%), strontium (2.7%) 
and raloxifene (2.6%); 54% with effective adherence (MPR > 50%). Fracture related 
costs (excluding medication costs) included direct medical, long-term nursing care, 
and work loss. The model parameters are adjustable, allowing real time calculation 
of outcomes. We estimated current costs with 54% effectively adherent and 100% 
effectively adherent. RESULTS: The model calculated total fracture-related costs for 
all patients in 2010 at c4.4 billion (with 69.6% for direct medical costs, 20.2% for 
long-term nursing care, and 10.2% for work loss). For the estimated 4.2% of treated 
patients, the model calculated total fracture-related costs at c184.9 million. Increasing 
the percentage of patients with effective adherence from 54% to 100% decreased costs 
for hip (16.2%), vertebral (24.4%) and NHNV fractures (6.3%). CONCLUSIONS: 
Adjustable parameters allow users to calculate yearly fracture-related costs and savings 
for different economic perspectives and decision options. According to one run using 
the above parameters, achieving full adherence to medication among women currently 
treated for osteoporosis in Germany would reduce fractures, and cut down annual 
fracture related costs by c27.8 million (15.1%).
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OBJECTIVES: To evaluate the cost-effectiveness of certolizumab pegol (CZP) either 
as an add-on therapy to methotrexate (MTX) or as monotherapy versus other biologi-
cal DMARDs, in the treatment of patients with active RA who did not respond 
adequately to DMARDs, including MTX, in the United Kingdom (UK). METHODS: 
A cost-utility model with a Markov structure was developed following BSR and NICE 
guidelines. Comparators considered in the analysis were licensed and recommended 
TNF-α inhibitors in England and Wales (etanercept [ETA], adalimumab [ADA] and 
inﬂ iximab [IFX]), + MTX or as monotherapy (ETA and ADA only). Clinical efﬁ cacy, 
history and resource use data came from published literature. Unit costs were taken 
from routine sources/published references. Utilities were derived from EQ-5D data 
collected in CZP RA clinical trials. Cost for CZP assumed the ﬁ rst 12 weeks free of 
charge, as per the patient access scheme. Base-case analysis was conducted from the 
NHS perspective, with lifetime horizon, costs and outcomes discounting rates of 3.5%. 
Sensitivity analyses were conducted. RESULTS: Base-case analysis indicated that CZP 
is cost-effective compared with all combination and monotherapies considered. 
CZP+MTX dominated the comparators considered. CZP+MTX was associated with an 
incremental gain in quality-adjusted life-years (QALYs) of 0.242, 0.065 and 0.458 when 
compared with ADA+MTX, ETA+MTX and IFX+MTX, respectively. Total costs for 
CZP+MTX were lower than comparator combination therapies by £451, £582 and 
£10,016, respectively. CZP+MTX had the highest probability of being cost-effective of 
the TNF inhibitor + MTX therapies considered (at £20,000/QALY, 53.6% for 
CZP+MTX, 25% for ETA+MTX, 21.2% for ADA+MTX, 0.2% for IFX+MTX). 
Among monotherapies, CZP dominated ADA (QALY incremental gain: 0.215, total 
costs lower by £2,352 vs. ADA). CZP was cost-effective below a willing-to-pay threshold 
of £31,582/QALYs vs. ETA. CONCLUSIONS: This analysis indicates that CZP is a 
cost-effective treatment for RA in the UK.
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OBJECTIVES: To assess the cost-utility and multinomial expected value of perfect 
information (mEVPI) of sequenced treatment with biologics in moderate-to-severe 
rheumatoid arthritis (msRA) after failure of traditional disease modifying antirheu-
matic drug(s) (tDMARD). METHODS: A probabilistic, individual sampling (micro-
simulation) model was developed to compare ten different treatment sequences 
among 3,000 hypothetical Finnish msRA patients in a lifetime scenario. 
Adalimumab+methotrexate (MTX), etanercept+MTX or tocilizumab+MTX were 
used as ﬁ rst biologics followed by up to three other biologics. Best supportive care 
including tDMARDs was assumed to be used after exhaustion of treatment options 
with biologics. Treatment with MTX alone was added as further comparator. The 
clinical outcomes (no ACR50, ACR50 and ACR70 responses conditional to the use 
of biologic drugs) were obtained from a recently published mixed treatment compari-
son and quality-adjusted life-years (QALY) were estimated based on disease severity 
scores (HAQ) using a nonlinear equation: EQ5D = 0.82-0.11*HAQ-0.07*HAQ2. 
Resource use was estimated from published references and valued with Finnish unit 
costs (year 2009). Analyses were performed from payer perspective (productivity losses 
were excluded) using 3% annual discount rate. RESULTS: Compared to MTX alone, 
treatment with tocilizumab+MTX was more cost-effective than treatment with 
etanercept+MTX. Both tocilizumab+MTX and etanercept+MTX dominated 
adalimumab+MTX. An additional QALY gained with tocilizumab+MTX costs 
c15,478 (mEVPI c1,258/patient) compared with MTX alone. An additional QALY 
gained with tocilizumab+MTX followed by etanercept+MTX costs c35,543 (mEVPI 
c748/patient) compared with tocilizumab+MTX. According to cost-effectiveness 
acceptability frontier, only MTX alone, tocilizumab+MTX or tocilizumab+MTX fol-
lowed by etanercept+MTX should be considered, if willingness to pay is c0–50,000 
per QALY gained. With c30,000 per QALY gained, tocilizumab+MTX had 97.6% 
probability of being cost-effective. The results were relatively robust in sensitivity 
analyses. CONCLUSIONS: After tDMARD failure, tocilizumab+MTX or 
tocilizumab+MTX followed by etanercept+MTX were the most cost-effective biolog-
ics for patients with msRA. mEVPI indicated that the value of additional research 
information is low.
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OBJECTIVES: To measure the impact of obesity on annual medical and productivity 
costs among working U.S. adults with arthritis. METHODS: We conducted a cross 
sectional study using Medical Expenditure Panel Survey data from 2003–2007. 
Working adults with arthritis (18–64 years old) were selected if they did not have 
pregnancy, malignancy, kidney dialysis, immunodeﬁ ciency, low body mass index (BMI 
< 18.5 kg/m2), or unemployed status. Patients with arthritis were identiﬁ ed by ICD-9 
codes of 714–715 or via patient self-report. Obese and normal- weight were deﬁ ned 
as BMI of ≥30 kg/m2 or BMI of 18.5–<25 kg/m2, respectively. Loss of productivity 
was estimated by loss of workdays due to illness or injury and standard hourly wage 
by occupation. Medical costs were estimated using a generalized linear model with a 
log link function and gamma distribution. Costs of productivity loss were calculated 
using a two-part model to adjust for patients with zero costs. Using Oaxaca decom-
position, differences in treatment costs between obese and normal-weight patients 
were decomposed into two parts: a) differences in characteristics (endowments) across 
groups, and b) differences between obese and normal parameters (coefﬁ cients). Costs 
attributable to obesity were deﬁ ned as the costs by coefﬁ cients component. All costs 
were converted to 2009 U.S. dollars using price indices. RESULTS: Among the 7345 
working adults with arthritis, prevalence of obesity and normal-weight was 24.8% 
vs. 40.7%, respectively. The difference in medical costs between the groups was 
US$2380 (95% CI: US$1934–2825) due to endowments and US$379 (95% CI: 
US$367–392) due to coefﬁ cient components. Productivity loss costs in the obese 
patients were higher, at US$46(95% CI: US$ 41–51) due to endowments and 
US$441(95%CI: US$435–447) due to coefﬁ cient components. CONCLUSIONS: Use 
of the Oaxaca decomposition method suggested that the economic burden, particu-
larly productivity loss costs, of obesity in patients with arthritis was substantial, 
adjusting for characteristics across groups.
